email article
Cabozantinib (Cabometyx) came out on top as upfront therapy in metastatic papillary renal cell carcinoma (RCC) in a randomized phase II study.
Treatment with the multikinase inhibitor yielded a median progression-free survival (PFS) of 9.0 months, as compared to 5.6 months with sunitinib (Sutent), which has been the default standard of care in this setting (HR 0.60, 95% CI 0.37-0.97, one-sided
P=0.019), reported Sumanta Pal, MD, of City of Hope Comprehensive Cancer Center in Duarte, California.
Overall response rate was significantly improved with cabozantinib compared with sunitinib (23% vs 4%,
P=0.01), and 5% versus none, respectively, had complete responses, according to findings presented at the virtual Genitourinary Cancers Symposium (GUCS) and published simultaneously in the
A new study from Washington University School of Medicine in St. Louis demonstrates that a liquid biopsy examining blood or urine can help gauge the effectiveness of therapy for colorectal cancer that has just begun to spread beyond the original tumor.
AbbVie and Caribou Biosciences have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics.